Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Red Cross Blood Service, Kalgoorlie, WA

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, ensuring that they are safe, of high quality, and effective for their intended use. The Act was introduced to address the need for a comprehensive regulatory framework that governs the manufacturing, distribution, and advertising of therapeutic goods, including medicines, medical devices, and blood products. The Act is overseen by the Parliament of Australia and the Therapeutic Goods Administration (TGA), which is the agency responsible for the regulation of therapeutic goods in the country. One of the primary policy objectives of the Act is to protect public health by ensuring that therapeutic goods are only supplied if they meet certain standards of quality, safety, and efficacy. In line with this objective, the TGA has the authority to revoke a licence to manufacture therapeutic goods if the holder of the licence no longer meets the necessary requirements or if the licence is revoked at the request of the manufacturer. This power is exercised under Section 41(1)(d) of the Act, which allows the Secretary to revoke a licence by notice in writing. The revocation of a licence means that the manufacturer is no longer authorised to manufacture therapeutic goods, which can have significant implications for the availability of those goods in the market. The TGA exercises this power to ensure that only manufacturers who meet the necessary requirements are allowed to supply therapeutic goods to the public.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity engaged in the manufacture, supply, or importation of therapeutic goods within Australia. This includes medical devices, medicines, and blood and blood components, among other items, and encompasses a range of conduct and transactions involving these goods. The Act is administered by the Therapeutic Goods Administration, which is part of the Commonwealth Department of Health, thus it has a national jurisdictional reach. The revocation of a licence under Section 41(1)(d) of the Act is a specific application of its provisions, indicating that the legislation allows for the regulation and oversight of the entities and individuals involved in the production of therapeutic goods. In this instance, the revocation pertains to the Australian Red Cross Blood Service, demonstrating the Act’s capacity to control entities involved in the manufacture of blood and blood components. The Act does not explicitly state exclusions or thresholds but may extend its application through subordinate instruments such as regulations and guidelines, which provide further detail on the types of goods and activities subject to its purview.

Key Provisions

The Therapeutic Goods Act 1989 (Section 41(1)(d)) allows the Secretary to revoke a licence for the manufacture of therapeutic goods under certain conditions. In this case, the Australian Red Cross Blood Service, operating as a division of The Australian Red Cross Society, had its licence revoked for the Blood Donor Centre in Kalgoorlie. The licence in question is MI-24082005-LI-000851-1. This revocation was executed at the request of the manufacturer, and it is formalised through a written notice. This legislative provision ensures that the quality and safety of therapeutic goods are maintained by permitting the Secretary to take such actions when necessary. The Act imposes certain obligations on entities that hold licences to manufacture therapeutic goods. These obligations include ensuring compliance with all relevant standards, regulations, and guidelines set by the Therapeutic Goods Administration. This involves maintaining accurate records, reporting any adverse events, and adhering to Good Manufacturing Practices (GMP). For the Australian Red Cross Blood Service, this meant that they were responsible for the quality and safety of the blood products they were manufacturing and distributing. Failure to meet these obligations could result in the revocation of their licence. Breaches of the Therapeutic Goods Act 1989 can lead to various penalties and consequences. Under the Act, if a manufacturer fails to comply with the regulations, they may face administrative penalties, including fines. Additionally, more severe breaches could result in criminal charges, which could lead to substantial fines and imprisonment. The specific penalties depend on the nature and severity of the breach. For instance, knowingly supplying unsafe therapeutic goods can result in fines of up to $1.1 million for individuals and $5.5 million for bodies corporate, along with potential imprisonment terms. These measures are designed to deter non-compliance and ensure the safety and efficacy of therapeutic goods available in Australia.